Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Plus Capecitabine vs Capecitabine in TNBC With Residual Disease
NCT03756298Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2019
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jan 2019; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03756298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03756298.